2018
Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial
Edelman EJ, Moore BA, Holt SR, Hansen N, Kyriakides TC, Virata M, Brown ST, Justice AC, Bryant KJ, Fiellin DA, Fiellin LE. Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial. AIDS And Behavior 2018, 23: 211-221. PMID: 30073637, PMCID: PMC6476298, DOI: 10.1007/s10461-018-2241-z.Peer-Reviewed Original ResearchConceptsHIV-positive patientsHeavy drinking daysVACS Index scoreXR-NTXART adherenceDrinking daysIndex scoreUndetectable HIV viral loadCD4 cell countExtended-release naltrexoneDouble-blind placeboHIV viral loadRandomized-controlled trialDrinking outcomesHIV biomarkersSecondary outcomesHIV outcomesPrimary outcomeViral loadAntiretroviral adherenceClinical trialsCell countAlcohol treatmentHIVPatients
2016
Interim Buprenorphine vs. Waiting List for Opioid Dependence
Sigmon SC, Ochalek TA, Meyer AC, Hruska B, Heil SH, Badger GJ, Rose G, Brooklyn JR, Schwartz RP, Moore BA, Higgins ST. Interim Buprenorphine vs. Waiting List for Opioid Dependence. New England Journal Of Medicine 2016, 375: 2504-2505. PMID: 28002704, PMCID: PMC5373028, DOI: 10.1056/nejmc1610047.Peer-Reviewed Original ResearchMeSH KeywordsBuprenorphineHumansNarcotic AntagonistsOpioid-Related DisordersPilot ProjectsWaiting Lists
2014
Primary Care–Based Buprenorphine Taper vs Maintenance Therapy for Prescription Opioid Dependence: A Randomized Clinical Trial
Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O’Connor P. Primary Care–Based Buprenorphine Taper vs Maintenance Therapy for Prescription Opioid Dependence: A Randomized Clinical Trial. JAMA Internal Medicine 2014, 174: 1947-1954. PMID: 25330017, PMCID: PMC6167926, DOI: 10.1001/jamainternmed.2014.5302.Peer-Reviewed Original ResearchConceptsPrescription opioid dependenceOngoing maintenance therapyIllicit opioid useMaintenance therapyOpioid dependenceBuprenorphine taperBuprenorphine therapyTaper groupMaintenance groupOpioid usePrimary careClinical trialsPrimary care-based treatmentSignificant public health burdenBuprenorphine maintenance therapyOngoing maintenance treatmentPrimary care physiciansEvidence-based guidelinesPrimary care sitesPublic health burdenWeeks of stabilizationHydrochloride therapyOpioid withdrawalBuprenorphine treatmentNaltrexone treatment
2013
HIV Testing and Sexual Risk Reduction Counseling in Office-Based Buprenorphine/Naloxone Treatment
Edelman EJ, Moore BA, Caffrey S, Sikkema KJ, Jones ES, Schottenfeld RS, Fiellin DA, Fiellin LE. HIV Testing and Sexual Risk Reduction Counseling in Office-Based Buprenorphine/Naloxone Treatment. Journal Of Addiction Medicine 2013, 7: 410-416. PMID: 24189173, DOI: 10.1097/adm.0b013e3182a3b603.Peer-Reviewed Original ResearchConceptsSexual risk reduction counselingRisk reduction counselingBuprenorphine/naloxone treatmentOpioid-dependent patientsReduction counselingSexual risk behaviorsHIV testingNaloxone treatmentHuman immunodeficiency virus (HIV) testingRisk behaviorsPreliminary efficacyVirus testingPatientsManual adherenceTreatment practicesProcess measuresCounseling sessionsSimilar proportionsHIVCounselingOutcomesTreatmentSessionsRandomizedTesting
2012
Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients
Tetrault JM, Moore BA, Barry DT, O'Connor PG, Schottenfeld R, Fiellin DA, Fiellin LE. Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients. Journal Of Substance Use And Addiction Treatment 2012, 43: 433-439. PMID: 22938914, DOI: 10.1016/j.jsat.2012.07.011.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineBuprenorphine, Naloxone Drug CombinationCounselingDelivery of Health Care, IntegratedFeasibility StudiesFemaleFollow-Up StudiesHIV InfectionsHumansMaleMiddle AgedNaloxoneNarcotic AntagonistsOpioid-Related DisordersPsychotherapy, BriefSubstance Abuse DetectionTime FactorsTreatment OutcomeViral LoadConceptsEnhanced medical managementPhysician managementDetectable HIV viral loadHIV treatment settingsOpioid-negative urinesBuprenorphine/naloxoneHIV viral loadOpioid-dependent patientsPercentage of subjectsUntreated opioid dependenceExtended counselingHIV clinicHIV outcomesBuprenorphine/Medical managementOpioid dependenceViral loadDependent patientsExtensive counselingClinical trialsContinuous abstinenceNegative urineTreatment settingsGroup differencesCounselingCost-Effectiveness of Long-Term Outpatient Buprenorphine-Naloxone Treatment for Opioid Dependence in Primary Care
Schackman BR, Leff JA, Polsky D, Moore BA, Fiellin DA. Cost-Effectiveness of Long-Term Outpatient Buprenorphine-Naloxone Treatment for Opioid Dependence in Primary Care. Journal Of General Internal Medicine 2012, 27: 669-676. PMID: 22215271, PMCID: PMC3358393, DOI: 10.1007/s11606-011-1962-8.Peer-Reviewed Original ResearchMeSH KeywordsBuprenorphineCost of IllnessCost-Benefit AnalysisDecision Support TechniquesDrug Administration ScheduleDrug CombinationsDrug CostsHealth Care CostsHumansLong-Term CareMedication AdherenceNaloxoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPrimary Health CareQuality-Adjusted Life YearsSensitivity and SpecificityUnited StatesConceptsQuality-adjusted life yearsBUP/NXProbabilistic sensitivity analysesBup/Stable patientsOpioid dependenceLife weightsStable opioid-dependent patientsIncremental cost-effectiveness ratioOpioid-dependent patientsOpioid-dependent individualsOffice-based settingSocietal cost savingsCost-effectiveness ratioDecision analytic modelBroader health systemBuprenorphine-naloxoneOpioid useCohort studyNaloxone treatmentCare physiciansAdditional researchPrimary carePatient costsHypothetical cohort
2006
A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care
Sullivan LE, Barry D, Moore BA, Chawarski MC, Tetrault JM, Pantalon MV, O'Connor PG, Schottenfeld RS, Fiellin DA. A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care. Clinical Infectious Diseases 2006, 43: s184-s190. PMID: 17109305, DOI: 10.1086/508182.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, SublingualAdultAntiretroviral Therapy, Highly ActiveBuprenorphineDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHIV InfectionsHumansMaleMiddle AgedNaloxoneNarcotic AntagonistsOpioid-Related DisordersPilot ProjectsProbabilityReference ValuesRisk FactorsTreatment OutcomeConceptsHIV clinical careHIV-1 RNA copies/mLBuprenorphine/naloxone treatmentRNA copies/mLCopies/mLOpioid dependenceClinical careOpioid useNaloxone treatmentPhysician managementTreatment retentionHIV type 1 RNA levelsHIV-1 RNA levelsDose of buprenorphinePartial opioid agonistRNA levelsCD4 lymphocyte countBuprenorphine/naloxoneOpioid-dependent patientsUrine toxicology testsWeeks of treatmentHuman immunodeficiency virusUrine test resultsBetter treatment retentionUntreated opioid dependenceCounseling plus Buprenorphine–Naloxone Maintenance Therapy for Opioid Dependence
Fiellin DA, Pantalon MV, Chawarski MC, Moore BA, Sullivan LE, O'Connor PG, Schottenfeld RS. Counseling plus Buprenorphine–Naloxone Maintenance Therapy for Opioid Dependence. New England Journal Of Medicine 2006, 355: 365-374. PMID: 16870915, DOI: 10.1056/nejmoa055255.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineCocaine-Related DisordersCombined Modality TherapyCounselingFemaleHumansMaleNaloxoneNarcotic AntagonistsOpioid-Related DisordersConceptsStandard medical managementBuprenorphine-naloxone treatmentIllicit opioid useMedical managementOpioid dependenceWeekly medicationOpioid useIllicit opioidsWeekly counselingPrimary careUrine specimensConsecutive weeksProportion of patientsImproved treatment outcomesMaintenance therapyPrimary outcomeClinical trialsMedication distributionSimilar efficacyTreatment outcomesMedicationsSelf-reported frequencyPatientsFrequency of attendanceMean percentage